Priority Research Papers:

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas

Jane B. Cryan, Sam Haidar, Lori A. Ramkissoon, Wenya Linda Bi, David S. Knoff, Nikolaus Schultz, Malak Abedalthagafi, Loreal Brown, Patrick Y. Wen, David A. Reardon, Ian F. Dunn, Rebecca D. Folkerth, Sandro Santagata, Neal I. Lindeman, Azra H. Ligon, Rameen Beroukhim, Jason L. Hornick, Brian M. Alexander, Keith L. Ligon and Shakti H. Ramkissoon _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:8083-8092. https://doi.org/10.18632/oncotarget.2342

Metrics: PDF 3060 views  |   HTML 3795 views  |   ?  


Jane B. Cryan1, Sam Haidar2, Lori A. Ramkissoon2, Wenya Linda Bi4, David S. Knoff2, Nikolaus Schultz6, Malak Abedalthagafi1, Loreal Brown2, Patrick Y. Wen2, David A. Reardon2, Ian F. Dunn4, Rebecca D. Folkerth1, Sandro Santagata1,3, Neal I. Lindeman1, Azra H. Ligon1, Rameen Beroukhim2, Jason L. Hornick1, Brian M. Alexander5, Keith L. Ligon1,2,3 and Shakti H. Ramkissoon1,2,3

1 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

3 Department of Pathology, Harvard Medical School, Boston, MA, USA

4 Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA, USA

5 Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

6 Kravis Center for Molecular Oncology & Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA


Shakti Ramkissoon, email:

Keith Ligon, email:

Keywords: oligodendroglioma, astrocytoma, oligoastrocytoma, sequencing, IDH

Received: June 02, 2014 Accepted: August 11, 2014 Published: August 12, 2014


Classifying adult gliomas remains largely a histologic diagnosis based on morphology; however astrocytic, oligodendroglial and mixed lineage tumors can display overlapping histologic features. We used multiplexed exome sequencing (OncoPanel) on 108 primary or recurrent adult gliomas, comprising 65 oligodendrogliomas, 28 astrocytomas and 15 mixed oligoastrocytomas to identify lesions that could enhance lineage classification. Mutations in TP53 (20/28, 71%) and ATRX (15/28, 54%) were enriched in astrocytic tumors compared to oligodendroglial tumors of which 4/65 (6%) had mutations in TP53 and 2/65 (3%) had ATRX mutations. We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at frequencies similar to pure astrocytic tumors, suggesting that oligoastrocytomas and astrocytomas may represent a single genetic or biological entity. p53 protein expression correlated with mutation status and showed significant increases in astrocytomas and oligoastrocytomas compared to oligodendrogliomas, a finding that also may facilitate accurate classification. Furthermore our OncoPanel analysis revealed that 15% of IDH1/2 mutant gliomas would not be detected by traditional IDH1 (p.R132H) antibody testing, supporting the use of genomic technologies in providing clinically relevant data. In all, our results demonstrate that multiplexed exome sequencing can support evaluation and classification of adult low-grade gliomas with a single clinical test.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2342